CASI PHARMACEUTICALS, INC. Debt Securities, Trading, and Equity Securities, FV-NI, Cost
CASI PHARMACEUTICALS, INC. (CASIF) had Debt Securities, Trading, and Equity Securities, FV-NI, Cost of $2.58 million as of 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost · last filed 2026-05-15
- 2025-12-31: Debt Securities, Trading, and Equity Securities, FV-NI, Cost $2.58M.
- 2024-12-31: Debt Securities, Trading, and Equity Securities, FV-NI, Cost $2.58M.
- 2023-12-31: Debt Securities, Trading, and Equity Securities, FV-NI, Cost $3.17M.
- 2022-12-31: Debt Securities, Trading, and Equity Securities, FV-NI, Cost $8.67M.
| Period end | Debt Securities, Trading, and Equity Securities, FV-NI, Cost |
|---|---|
| 2025-12-31 | $2.58M 20-F · filed 2026-05-15 |
| 2024-12-31 | $2.58M 20-F · filed 2026-05-15 |
| 2023-12-31 | $3.17M 20-F · filed 2025-03-31 |
| 2022-12-31 | $8.67M 20-F · filed 2024-03-28 |
| 2021-12-31 | $32.66M 20-F · filed 2023-04-26 |